Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies
(2024)
Journal Article
King, L. D., Pulido, D., Barrett, J. R., Davies, H., Quinkert, D., Lias, A. M., Silk, S. E., Pattinson, D. J., Diouf, A., Williams, B. G., McHugh, K., Rodrigues, A., Rigby, C. A., Strazza, V., Suurbaar, J., Rees-Spear, C., Dabbs, R. A., Ishizuka, A. S., Zhou, Y., Gupta, G., …Draper, S. J. (2024). Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies. Cell Reports Medicine, 5(7), Article 101654. https://doi.org/10.1016/j.xcrm.2024.101654
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called RH5.1/Matrix-M. We i...
Read More about Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.